Awakn Life Sciences Initiates Research Program to Further Develop Ketamine-Assisted Therapies for Treating Addiction Psychedelics Investing
Hollister Biosciences Inc. Added to Horizons US Marijuana Index ETF and Included in Solactive US Marijuana Companies Index Psychedelics Investing
Silo Wellness Announces Approval for Trading on the OTCQBÂ Under Symbol "SILFF" Psychedelics Investing
Awakn Establishes Separate Preclinical and Clinical Expert Advisory Boards to Optimize Delivery of Its Expanding Development Pipeline Psychedelics Investing
COMPASS Pathways to participate in Cowen's Psychedelics & Novel Mechanisms in Neuropsychiatry Virtual Summit Psychedelics Investing
Seelos Therapeutics Announces Positive In Vivo Data Demonstrating Down-Regulation of SNCA mRNA and Protein Expression from a Gene Therapy Study of SLS-004 Utilizing CRISPR-dCas9 for Parkinson's Disease Pathology Psychedelics Investing
Numinus Wellness To Acquire Neurology Centre of Toronto, Plans to Create Centre for Psychedelic Neurology Cannabis Investing News
Seelos Therapeutics Doses First Patient in Part 2 of a Registrational Study of SLS-002 for Acute Suicidal Ideation and Behavior in Patients with Major Depressive Disorder Psychedelics Investing
COMPASS Pathways joins forces with King's College London and South London and Maudsley NHS Foundation Trust to accelerate psychedelic research and develop new models of mental health care in the UK Psychedelics Investing
Lobe Sciences Advances Governance and Capital Markets Expertise with Appointment of Mr. Nick Karakochuk to the Board of Directors
